ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumoniaIgnacio Martín‐Loeches, Richard G. Wunderink, Antoni Torres et al.|Intensive Care Medicine|2023Cited by 289
Rationalizing antimicrobial therapy in the ICU: a narrative reviewJean‐François Timsit, François Barbier, Matteo Bassetti et al.|Intensive Care Medicine|2019Cited by 266
ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumoniaIgnacio Martín‐Loeches, Richard G. Wunderink, Antoní Torres et al.|European Respiratory Journal|2023Cited by 139
Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trialPierre‐François Laterre, Anne-Aurore Duchambon, Jean-Claude Lachérade et al.|Intensive Care Medicine|2021Cited by 92
Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical TrialsEmmanuel Weiss, Jean‐François Timsit, Jean‐Ralph Zahar et al.|Clinical Infectious Diseases|2019Cited by 49